{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T16:54:59Z","timestamp":1788540899491,"version":"build-2803163510"},"reference-count":15,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2018,4,26]],"date-time":"2018-04-26T00:00:00Z","timestamp":1524700800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100007132","name":"Otsuka Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007132","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Psychiatry Clin Neurosci"],"published-print":{"date-parts":[[2018,6]]},"abstract":"<jats:sec><jats:title>Aim<\/jats:title><jats:p>This study assessed the long\u2010term safety, tolerability, and maintenance of the therapeutic effect of brexpiprazole in Japanese patients with schizophrenia.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This 52\u2010week, open\u2010label, flexible\u2010dose (1\u20134 mg\/day) study included patients with schizophrenia who continued treatment from a short\u2010term randomized placebo\u2010controlled fixed\u2010dose (1, 2, or 4 mg\/day) trial and de novo patients who switched from other antipsychotics.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 282 patients (184 de novo and 98 rolled over from short\u2010term trial) entered the 52\u2010week treatment with brexpiprazole, and 150 (53.2%) patients completed the week\u201052 assessment. Treatment\u2010emergent adverse events (TEAE) were experienced by 235\/281 patients (83.6%), and TEAE reported by \u226510% of all patients were nasopharyngitis (23.1%) and worsening of schizophrenia (22.4%). During the study, most of the TEAE were mild or moderate in severity, and there were no deaths, and no clinically meaningful mean changes in laboratory values, vital signs, or electrocardiogram parameters. Mean scores for the Positive and Negative Syndrome Scale total and Clinical Global Impression\u2013Severity remained stable until week 52.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Brexpiprazole was generally safe and well tolerated and maintained therapeutic effects in the long\u2010term treatment of Japanese patients with schizophrenia.<\/jats:p><\/jats:sec>","DOI":"10.1111\/pcn.12654","type":"journal-article","created":{"date-parts":[[2018,3,27]],"date-time":"2018-03-27T06:46:34Z","timestamp":1522133194000},"page":"445-453","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Long\u2010term safety and effectiveness of brexpiprazole in Japanese patients with schizophrenia: A 52\u2010week, open\u2010label study"],"prefix":"10.1111","volume":"72","author":[{"given":"Jun","family":"Ishigooka","sequence":"first","affiliation":[{"name":"Institute of CNS Pharmacology  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuichi","family":"Iwashita","sequence":"additional","affiliation":[{"name":"Headquarters of Clinical Development Otsuka Pharmaceutical Co., Ltd.  Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9752-8949","authenticated-orcid":false,"given":"Yoshihiro","family":"Tadori","sequence":"additional","affiliation":[{"name":"Department of Medical Affairs Otsuka Pharmaceutical Co., Ltd.  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,4,26]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-244X-13-50"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.3109\/15622975.2012.739708"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60733-3"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.08r04210"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2011.156"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-9338(10)71701-6"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-244X-12-20"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.114.213793"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2015.14101275"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2015.01.038"},{"key":"e_1_2_8_12_1","article-title":"Efficacy and safety of brexpiprazole (OPC\u201034712) as maintenance treatment in adults with schizophrenia: A randomized, double\u2010blind, placebo\u2010controlled study","author":"Fleischhacker WW","year":"2017","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2016.04.013"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v58n1205"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-006-0564-3"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852900000456"}],"container-title":["Psychiatry and Clinical Neurosciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fpcn.12654","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/pcn.12654","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/pcn.12654","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/pcn.12654","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,10]],"date-time":"2023-09-10T07:28:20Z","timestamp":1694330900000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/pcn.12654"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,26]]},"references-count":15,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["10.1111\/pcn.12654"],"URL":"https:\/\/doi.org\/10.1111\/pcn.12654","archive":["Portico"],"relation":{},"ISSN":["1323-1316","1440-1819"],"issn-type":[{"value":"1323-1316","type":"print"},{"value":"1440-1819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,26]]},"assertion":[{"value":"2018-01-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-03-21","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-04-26","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}